Carbapenem-resistant Enterobacteriaceae has become a significant public health concern as hospital outbreaks are now being frequently reported and these organisms are becoming difficult to treat with the available antibiotics.
INTRODUCTION
Carbapenem-resistant Enterobacteriaceae (CRE) has become a significant public health concern as hospital outbreaks are now being frequently reported and these organisms are becoming difficult to treat with the available antibiotics. Early recognition through molecular characterization, epidemiologic studies, and surveillance is essential to prevent hospital outbreaks of these organisms [1] . Serratia marcescens (S. marcescens), an aerobic Gram-negative pathogen belonging to the family of Enterobacteriaceae, is known to cause hospital-acquired infections, commonly in an outbreak setting. Carbapenem resistance in S. marcescens may be chromosomal (SME), or plasmid (KPC, Oxa-48, IMP, NDM and VIM) mediated. Carbapenem resistance in is an ominous event as this pathogen is intrinsically resistant to polymyxins [2] . S. marcescens outbreaks in intensive care units (ICUs) are associated with considerable mortality rates, ranging from 14% to 60% [3, 4] . Previous S. marcescens outbreaks in Italy has been mostly reported in neonatal ICUs (NICUs) [5] [6] [7] [8] [9] . The present study aimed to describe the first Italian nosocomial outbreak of VIM-producing S. marcescens occurred in our adult polyvalent ICU located in Campania region, Southern Italy.
CASE PRESENTATION

Chief complaints and history of illness
The index case of the outbreak of three patients infected and/or colonized by VIMproducing S. marcescens was a 49-year-old man with a history of schizophrenia admitted with a diagnosis of descending necrotizing mediastinitis whose CRE screening at admission was negative.
The second patient was a 69-year-old woman with a history of recurrent episodes of urinary tract infection (UTI) admitted from the community with UTI and septic shock (SS).
The third patient was a 67-year-old woman with various underlying diseases (Paranoid personality disorder, diabetes mellitus, ulcerative colitis, hypothyroidism and hypertrophic cardiomyopathy) who was admitted to our ICU for a hypovolemic haemorrhagic shock.
Examinations
For every patient admitted to our six-bed adult polyvalent ICU, a rectal swab (RS) was obtained (CRE screening) using a Copan Amies sterile transport swab (Copan Diagnostics, Murrieta, CA). The RS was streaked onto Mac Conkey Agar (Biomerieux, Marcy l'Etoule, France) with a 10 μg meropenem disk. Mac Conkey agar plates were incubated aerobically at 37°C overnight. Antibiotic susceptibility was determined using the disk diffusion method. Suspicious colonies growing into the meropenem disk-halo were picked up and identified using MALDI-TOF MS (Matrix-Assisted Laser Desorption/Ionization Time of Flight mass spectroscopy).
Carbapenem resistance were identified in accordance with the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines using updated EUCAST breakpoint tables (EUCAST clinical breakpoint valid from 15/05/2018) ( Table 1) . Molecular analysis to identify carbapenemase genes was performed using the Xpert Carba-R Cartridge (GeneXpert ® , Cepheid, Sunnyvale, CA).
The Xpert Carba-R Assay, conducted on the GeneXpert ® device, is an automated qualitative real-time polymerase chain reaction based test that detects specific gene associated with carbapenem resistance(blaKPC , blaNDM, blaVIM, blaOXA-48 and blaIMP-1).
FINAL DIAGNOSIS
After 65 d of the first patient hospitalization, a blood culture grew VIM-producing S. marcescens. Three days after the diagnosis of bacteraemia his RS was positive for the same organism. The same patient developed a new episode of bacteraemia during further ICU stay.
The second patient, eleven days after admission in ICU, developed lower respiratory tract infection (LRTI) with bronchial culture positive for VIM-producing S. marcescens. Her RS also tested positive for S. marcescens on the same day.
VIM-producing S. marcescens was isolated in the third patient from tracheal aspirate after seven days and from urine after eleven days of hospitalization. In both cases, the isolated was considered as a contaminant. During the ICU admission she developed an acute respiratory distress syndrome due to Enterococcus faecium.
TREATMENT
The first episode of VIM-producing S. marcescens bacteraemia was treated with ceftazidime-avibactam (CZA) plus gentamicin for 14-d. The second episode was initially treated with amikacin (AMK) and Fosfomycin. Fosfomycin was later substituted with meropenem due to hypernatremia. The total duration of the antibiotic treatment in this episode was 47 d.
The second patient was treated by the ward of origin with piperacillin-tazobactam (TZP) in association with AMK; initially (September, 12) we treated the SS with ceftolozane-tazobactam (C/T) and metronidazole; ceftaroline, not active against VIMproducing S. marcescens, was added later (September, 24), as her condition deteriorated, for a suspected methicillin-resistant Staphylococcus aureus infection [10] . The duration of total antibiotic therapy was 14 d.
The third patient was initially empirically treated with tigecycline and TZP; subsequently, due to the worsening of clinical conditions, antibiotic therapy was modified with the introduction of CZA, AMK, Colistin and ampicillin-sulbactam. VIM-producing S. marcescens, considered as a contaminant, in the third patient was not treated.
OUTCOME AND FOLLOW-UP
Both episodes of bacteraemia of the first patient resulted in a favourable outcome: The patient was transferred to a rehabilitation unit at the end of the ICU stay.
The second and the third patient died. Unfortunately for the third patient the microbiological result, with the isolation of the Enterococcus faecium, arrived posthumously.
The main clinical and epidemiological characteristics of the patients are reported in Table 2 .
DISCUSSION
S. marcescens is an essential cause of hospital-acquired infections. Although most infections have been linked to hospital outbreaks, occasional infections can occur outside the outbreak settings also. The first hospital outbreak was reported in San Francisco in 1950 where 11 patients developed UTI by S. marcescens, one of them complicated by endocarditis [11] . Many hospital outbreaks have been reported after that [12] . It has been associated with various infections including UTI, bloodstream infection, pneumonia, skin and soft tissue infections, meningitis and ocular infections. Antibiotic resistance has been a worrisome issue to physicians treating infections caused by S. marcescens. This organism is intrinsically resistant to a large number of antibiotics including ampicillin, amoxicillin, amoxicillin-clavulanate, ampicillinsulbactam, narrow-spectrum cephalosporins, cefuroxime, nitrofurantoin, macrolides and polymixins [13] . It also carries a chromosomal AmpC beta-lactamase which when overexpressed can render all beta-lactams except carbapenems ineffective [14] . They also can produce plasmid-mediated extended spectrum beta-lactamase (ESBL) and carbapenemases. Carbapenemases in S. marcescens can be chromosomal (SME) or plasmid-mediated (KPC, OXA-48, IMP, VIM, and NDM). Quinolone resistance can arise due to alterations in gyrA, outer membrane proteins, and expression of efflux pumps [12] .
Carbapenem resistance can be devastating in case of Serratia infections considering its intrinsic resistance to polymixins. Many outbreaks of KPC2 producing Serratia marcescens has been reported [15, 16] . Plasmid-mediated Metallo-β-lactamases (IMP, VIM, and NDM-1) which inactivate carbapenems can be produced by some Serratia strains [17] .
Nosocomial outbreaks of VIM-producing S. marcescens has been reported infrequently in literature, most of them are from NICUs [18, 19] . Nosocomial outbreaks of VIM-producing pathogens have been reported in multiple major Gram-negative bacteria, making VIM-producing bacteria a severe public health concern. The first VIM-producing Gram-negative pathogen and the most frequently reported in the literature is Pseudomonas aeruginosa, followed by Klebsiella pneumonia and Acinetobacter baumannii ( Table 3 ). In our study, VIM-producing S. marcescens was isolated in a University Hospital ICU. This is in line with previous reports in the literature because most cases of VIM-producing Gram-negative pathogens have been isolated in ICUs of tertiary care teaching hospitals (Table 3) . Unlike what has been reported in the last ten years in our Country, where the S. marcescens outbreaks have mostly taken place in NICUs (Table 4 ) this first Italian outbreak of VIM-producing Serratia marcescens occurred in an adult ICU. Fatality rate in our outbreak was 50% (2 of 4 episodes), similar to the first nosocomial outbreak of VIM-producing S. marcescens happened in Argentina, which however occurred in NICU setting [19] . The high mortality is probably due to the inappropriate use of antibiotics for the treatment of severe infections in ICU patients [20] . In Figure 1 are represented the mechanisms of action of antibiotics used in our patients with VIM-producing S. marcescens infection. Given that no effective treatment is known, isolated reports describe successful therapy combining CZA and Aztreonam. The rationale of this antibiotic association is that Aztreonam remains intact in the presence of carbapenemases but hydrolyzed by ESBLs and CZA neutralizes the ESBLs and AmpC beta-lactamases [21] . In our study CZA was never co-administered with aztreonam, though there was clinical success in one of two patients who were given CZA in combination with other antibiotics ( Table  2 ).
CONCLUSION
We report the first European outbreak of VIM-producing Serratia marcescens in adult polyvalent ICUs. Two patients developed an infection (bacteremia and LRTI) while one had colonization. No effective therapy is available for the treatment of VIMproducing S. marcescens. Methods to detect expression of carbapenem resistance should be widely available in all health care units to prevent the spread of multi-drug organisms and to limit horizontal transfer of the genes associated with drug resistance. Such active surveillance methods will help in averting future outbreaks. 
